Aug 6, 2015 - Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) prolongs survival in selected patients with ...
Langenbecks Arch Surg (2015) 400:693–698 DOI 10.1007/s00423-015-1325-8
ORIGINAL ARTICLE
Overall morbidity but not mortality is increased in elderly patients following cytoreductive surgery and HIPEC Stefan Beckert 1 & Florian Struller 1 & Philipp Horvath 1 & Anya Falcke 1 & Alfred Königsrainer 1 & Ingmar Königsrainer 1,2
Received: 9 January 2015 / Accepted: 27 July 2015 / Published online: 6 August 2015 # Springer-Verlag Berlin Heidelberg 2015
Abstract Background Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) prolongs survival in selected patients with peritoneal metastases. Since this procedure is likely to be associated with increased morbidity and mortality, it remains controversial whether it is also suitable for patients older than 70 years. Methods Consecutive patients with radiographic evidence of peritoneal metastases (PM) were scheduled for CRS and HIPEC at the Comprehensive Cancer Center, University Hospital Tübingen, Germany. Clinical data were retrospectively analyzed categorizing patients with respect to age into elderly (age≥70) and non-elderly patients (age
